Participating Companies


CerSci Therapeutics
De­vel­op­ing a new gen­er­a­tion of non-opi­oid medicines to treat acute post-op­er­a­tive and chron­ic neu­ro­path­ic pain. Lead pro­gram in Phase 1 (MAD/SAD/Food Ef­fect), CT-044, tar­get­ing re­ac­tive spe­cies that cause neu­ro­n­al ion chan­nel hy­per-sen­si­ti­za­tion, known to trig­ger pain. [more in­for­ma­tion]
Forbius
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
Incysus Therapeutics
The com­pany's ser­vices fo­cus on uti­l­iz­ing ge­net­i­cal­ly mod­i­fied gam­ma-del­ta T cells across a Drug Re­sis­tance Im­munother­a­py (DRI) plat­form that ad­dress­es the chal­lenges faced while tar­get­ing cold, low mu­ta­tion can­cers, en­abling the tar­get­ing of ma­lig­nant cells and po­ten­tial­ly more ef­fec­tive treat­ments for pa­tients with dif­fi­cult-to-treat solid tu­mor can­cers. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$4,440 MM MCap
Late-stage cell ther­a­py com­pany uti­l­iz­ing pro­pri­e­tary au­tol­o­gous tu­mor in­fil­trat­ing lym­pho­cytes (TILs) to at­tack solid tu­mors. The com­pany is con­duct­ing piv­o­tal stage trials in me­tastat­ic me­lano­ma and ad­vanced cer­vi­cal can­cer with BLAs ex­pect­ed 2020. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$673 MM MCap
An­nounced pos. pri­mary anal­y­sis re­sults (May 2020) in piv­o­tal trial of ROCK in­hibi­tor-KD025 (Belu­mo­sudil) in cGVHD pts re­ceiv­ing 2+ pri­or ther­a­py lines; ORRs of 73% and 74% in 200mg QD and 200mg BID arms, re­spec­tive­ly. Belu­mo­sudil is be­ing re­viewed un­der Re­al-Time On­col­o­gy Re­view (RTOR) Pi­lot Pro­gram by the FDA; NDA sub­mis­sion exp Q4 2020. En­rolling pts in Ph 2 trial (sys. scle­ro­sis). [more in­for­ma­tion]
Zentalis [ZNTL] US$1,476 MM MCap
In ad­di­tion to its lead pro­gram, ZN-c5, an oral SERD for es­tro­gen re­cep­tor pos­i­tive, HER2-neg­a­tive breast can­cer, the Com­pany is de­vel­op­ing a broad pipe­line of on­col­o­gy can­di­dates, tar­get­ing ar­eas of ma­jor un­met med­i­cal need. [more in­for­ma­tion]
ZIOPHARM Oncology Inc [ZIOP] US$696 MM MCap
Cur­rent­ly en­rolling pa­tients in a phase 1 trials of Ad-RTS-hIL-12 as monother­a­py and in com­bi­na­tion with OP­DI­VO for the treat­ment of rGBM. [more in­for­ma­tion]